Literature DB >> 16260191

Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.

Kyunghwa Hwang1, Charity D Scripture, Martin Gutierrez, Shivaani Kummar, William D Figg, Alex Sparreboom.   

Abstract

A rapid method was developed for the quantitative determination of the novel heat shock protein 90 inhibitor, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG; NSC707545), in human plasma. Calibration curves were constructed, and were analyzed using a weight factor proportional to the nominal concentration. Sample pretreatment involved a one-step extraction with ethyl acetate of 0.5-ml samples. The analysis was performed in the range of 1-100 ng/ml on a column (75 mm x 2.1 mm internal diameter with 3.5 microm C18 particle size), using 55% methanol in water containing formic acid as the mobile phase. The column effluent was monitored by mass spectrometry with positive electrospray ionization. The values for precision and accuracy were always <8% and <10% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of 17-DMAG in a cancer patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260191     DOI: 10.1016/j.jchromb.2005.10.019

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

1.  In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.

Authors:  Nan Zheng; Peng Zou; Shaomeng Wang; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2010-12-22       Impact factor: 3.922

2.  Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.

Authors:  Xiaohong Chen; Erin R Gardner; Martin Gutierrez; Shivaani Kummar; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-23       Impact factor: 3.205

3.  A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.

Authors:  Zhe-Yi Hu; Jingtao Lu; Yuansheng Zhao
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

4.  HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.

Authors:  Thuy T Koll; Steven S Feis; Mollie H Wright; Modupe M Teniola; Mekel M Richardson; Ana I Robles; John Bradsher; Jacek Capala; Lyuba Varticovski
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.